The introduction of immunotherapy with immune checkpoint inhibitors (ICIs) targeting PD-1 and PD-L1 has revolutionized management of certain cancers, transforming short-term responses into durable clinical benefits [4, 5, 13, 14]. This evidence concerns the gene CD274 and cancer.